Sites: CDL-Oxford, CDL-Toronto, CDL-Vancouver, CDL-Wisconsin
Streams: Advanced Therapies, Cancer
As head of Johnson & Johnson Innovation at JLABS Canada, Dozie Amuzie is responsible for external engagement, innovation sourcing, company onboarding, portfolio management, operational excellence, educational programming and P&L. He catalyzes and supports the translation of science and technology into valuable solutions for patients and consumers across the pharmaceutical, medical device, consumer and healthtech sectors.
Dozie joined the JLABS team from the nonclinical safety -pathology function of the Discovery, Product Development and Supply Organization at the Janssen Pharmaceutical Companies of Johnson & Johnson where he led the U.S. discovery and project pathology team. Dozie and his team helped drive the acquisition and internal discovery of over 20 biopharmaceutical entities across 10 modalities from early discovery to clinical development, and some up to approval. He also initiated and led the cross-functional oligonucleotide working group that has helped shape strategies for RNAi therapies in discovery and was a critical driver for understanding the pathobiology of cancer immunotherapies in discovery and development.
Dozie earned a dual-major PhD in comparative medicine and integrative toxicological sciences at Michigan State University and completed a residency in veterinary pathology at Michigan State. He also received a D.V.M from University of Nigeria and is a diplomate with American Board of Toxicology, as well as a diplomate of American College of Veterinary Pathologists.
Dozie’s family love oceans and lakes, with a special connection to the Great Lakes, and are die-hard Michigan State Spartans. When Dozie is not thinking about new innovations for patients, he enjoys watching football and basketball with friends and family, supporting Philadelphia local sports teams, and the occasional teams with stand-out Spartans and/or Nigerians.